Clinical Trial Detail

NCT ID NCT02489903
Title RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors EpicentRx, Inc.
Indications

lung small cell carcinoma

lung non-small cell carcinoma

neuroendocrine tumor

Therapies

Etoposide

RRx-001

Carboplatin

Cisplatin

Nab-paclitaxel

Age Groups: adult

No variant requirements are available.